Organicell Regenerative Medicine, Inc

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL), a company focused on the development and commercialization of regenerative therapies, has released its quarterly report, revealing some interesting statistics and trends. In this 1500-word article, we’ll examine the key findings from the report and what they mean for the company’s future prospects. Gross Profit […]

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL) recently reached a settlement with Mr. Pepock and Ms. Yourke, resolving a legal dispute and leading to the repurchase of 24,800,001 shares of common stock for $500,000. The settlement marks the end of a contentious legal battle, as the repurchased shares were transferred back to

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL) recently raised $100,000 through the sale of more than 4.4 million shares at a price of $0.02244 each. The funds raised will be used for working capital and general corporate purposes. In parallel, the company has undergone significant executive changes, settled litigation by repurchasing 24.8

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL) recently released its quarterly report, revealing a net loss of $4,277,954 for the six months ended April 30, 2023. The company also stated an accumulated deficit of $54,799,260 and a stockholders’ deficit of $138,908 at the end of April 2023. Organicell is bolstering efforts to

Track all markets on TradingView Organicell Regenerative Medicine, Inc. (OCEL), a bio-pharmaceutical company specializing in the research, development, and commercialization of regenerative medicine therapies, has released their quarterly report for Q2 2023. During the six-month period ended April 30, 2023, Organicell reported revenues of $1.9 million, representing a strong financial performance for the company. Strong